Are you Dr. Aguirre?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 109 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
Boston, MA 02215Phone+1 617-632-3476Fax+1 617-582-7875
Summary
- Dr. Andrew Aguirre, MD is an oncologist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts. He is affiliated with Dana-Farber Cancer Institute and Brigham and Women's Hospital.
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2010 - 2013
Massachusetts General HospitalResidency, Internal Medicine, 2007 - 2010
Harvard Medical SchoolClass of 2007
Certifications & Licensure
MA State Medical License 2010 - 2026- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Author Correction: Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer.Urszula N Wasko, Jingjing Jiang, Tanner C Dalton, Alvaro Curiel-Garcia, A Cole Edwards
Nature. 2024-11-01 - Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer.Harshabad Singh, Joanne Xiu, Kevin S Kapner, Chen Yuan, Raja R Narayan
Clinical Cancer Research. 2024-11-01 - 10 citationsMechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer.Julien Dilly, Megan T Hoffman, Laleh Abbassi, Ziyue Li, Francesca Paradiso
Cancer Discovery. 2024-11-01
Authored Content
- Diabetes, Weight Change, and Pancreatic Cancer RiskAugust 2020
- Diabetes, Weight Change, and Pancreatic Cancer RiskAugust 2020
- Diabetes, Weight Change, and Pancreatic Cancer RiskAugust 2020
- Diabetes, Weight Change, and Pancreatic Cancer RiskAugust 2020
- Diabetes, Weight Change, and Pancreatic Cancer RiskAugust 2020
- Join now to see all
Press Mentions
KRAS Inhibitors in Pancreatic Cancer: Hope on the Horizon?September 9th, 2024- Can Chemo Help KRAS Inhibitors Work Better Against Pancreatic Cancer?August 20th, 2024
- Driving Progress Against RAS-Driven CancersMarch 29th, 2023
- Join now to see all
